Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Research ID

hum0473-v1Release info

Latest

Research title

Elucidation of the pathogenesis of hematopoietic neoplasms via genetic analysis / Molecular expression analysis of bone marrow cells from hematopoietic stem cell transplant donors as a normal control

Research overview

Aims
Genetic mutations in hematopoietic neoplasms, seen in disease-specific and non-specific ways, are key drivers in pathogenesis. Typically, these mutations alone don't cause neoplasms; rather, multiple mutations or breakdowns in regulatory mechanisms occur, progressing the disease through stages. Genetic mutation patterns vary even within subtypes, suggesting shared gene expression abnormalities from different mutations may drive neoplasm development. Identifying these "common factors" is vital for effective molecular-targeted therapy development. Our study aims to elucidate neoplasm pathogenesis by analyzing patient genetic abnormalities, pinpointing "common factors" in each subtype for novel targeted therapy development.
Methods
RNA sequencing
Participants/materials
Bone marrow CD34-positive cells from 57 patients with myelodysplastic syndromes (MDS) and 5 healthy individuals (62 participants in total)
URL
N/A

Datasets

CartDataset IDType of dataAnalysis methodAccess criteriaDate published
JGAD000857NGS (RNA-seq)
  • RNA-seq
Controlled-access (Type I)2025-06-30

Data provider

Principal investigator
Yuka Harada
Affiliation
Clinical Research and Trial Center, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

Research projects

NameURL
Elucidating the Pathogenesis of Hematological Malignancies via Genetic Analysis
N/A

Grants

NameTitleProject number
Clinical Research Fund of Tokyo Metropolitan Government
Developing a Comprehensive Diagnostic Approach for Myeloid Disorders Using AI to Guide Treatment Selection and Prognosis Prediction
  • R040301001
Clinical Research Fund of Tokyo Metropolitan Government
Developing a Diagnostic Approach for Myelodysplastic Syndromes Based on Abnormal Mitochondrial Dynamics
  • R050401011
KAKENHI Grant-in-Aid for Scientific Research (C)
Molecular diagnosis of myeloid neoplasms using targeted gene panel
  • JP20K07840
KAKENHI Grant-in-Aid for Scientific Research (B)
Chronic Inflammation via cGAS-STING Activation Triggered by Mitochondrial Fragmentation in Myelodysplastic Syndromes
  • JP22H02905
KAKENHI Grant-in-Aid for Scientific Research (C)
Development of a High-Precision Diagnostic System for Differentiating Myelodysplastic Syndromes and Bone Marrow Failure Syndromes
  • JP23K06899

Related publications

TitleDOIDataset ID
Unraveling the impact of crizotinib to promote megakaryopoiesis for alleviating thrombocytopenia in myelodysplastic neoplasms
https://doi.org/10.1038/s41375-025-02729-w (opens in a new tab)

Controlled access users

No use of the controlled access data has been recorded.